Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020
- 3 February 2021
- journal article
- research article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 214 (4), 179-185
- https://doi.org/10.5694/mja2.50940
Abstract
Objectives To estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney. Setting, participants People of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years. Design Cross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020. Main outcome measure Estimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity. Results Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors. Conclusions Estimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important.Keywords
Funding Information
- National Health and Medical Research Council
- NSW Ministry of Health
This publication has 7 references indexed in Scilit:
- COVID‐19 in Australia: our national response to the first cases of SARS‐CoV‐2 infection during the early biocontainment phaseInternal Medicine Journal, 2020
- Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic IndividualsFrontiers in Microbiology, 2020
- A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission SettingThe Journal of Infectious Diseases, 2020
- The Antibody Response to SARS-CoV-2 InfectionOpen Forum Infectious Diseases, 2020
- Serology testing in the COVID-19 pandemic responseThe Lancet Infectious Diseases, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Suppressing the Epidemic in New South WalesThe New England Journal of Medicine, 2020